WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
How a computer whiz duped the world into believing Katy Perry attended the 2024 Met GalaNew York Mets, St. Louis Cardinals game rained out, to be made up Aug. 564 people charged in sexual abuse investigations in Canada, Ontario police sayShopify's shares tumble on weak outlook after a very strong start to 2024Cease, 2 relievers combine on 1Rashee Rice warning sent to NFL teams before 2023 Draft amid Chiefs star's legal troublesCease, 2 relievers combine on 1Micah Leon's sevenChicago Fire star Eamonn Walker exits as series regular after 12 seasonsRangers reacquire OF Robbie Grossman in trade with White Sox
3.6231s , 6501.6953125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Gaze news portal